Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Simon two-stage study of olaparib in non-BRCA HRD metastatic breast cancer
2016-002892-80Phase 2Recruiting
- Sponsor
- MEDSIR
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in breast cancer, sponsored by MEDSIR. Primary endpoint: Clinical Benefit Rate. Started Jan 2018; status: recruiting.
02
Drugs
olaparib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2016-002892-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002892-80.